Clinical staging of malignant pleural mesothelioma: current perspectives

Maria Bonomi,1 Costantino De Filippis,2 Egesta Lopci,3 Letizia Gianoncelli,1 Giovanna Rizzardi,4 Eleonora Cerchiaro,1 Luigi Bortolotti,4 Alessandro Zanello,2 Giovanni Luca Ceresoli1 1Department of Oncology, Thoracic and GU Oncology Unit, 2Department of Radiology, Cliniche Humanitas Gavazzeni, Bergam...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Malignant Pleural Mesothelioma Staging Contrast-enhanced computed tomography Magnetic res-onance imaging Positron emission tomography Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ebedbd0f69fe4aa0b1a62eaa190b0c5b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ebedbd0f69fe4aa0b1a62eaa190b0c5b
record_format	dspace
spelling	oai:doaj.org-article:ebedbd0f69fe4aa0b1a62eaa190b0c5b2021-12-02T07:08:01ZClinical staging of malignant pleural mesothelioma: current perspectives1179-2728https://doaj.org/article/ebedbd0f69fe4aa0b1a62eaa190b0c5b2017-08-01T00:00:00Zhttps://www.dovepress.com/clinical-staging-of-malignant-pleural-mesothelioma-current-perspective-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Maria Bonomi,1 Costantino De Filippis,2 Egesta Lopci,3 Letizia Gianoncelli,1 Giovanna Rizzardi,4 Eleonora Cerchiaro,1 Luigi Bortolotti,4 Alessandro Zanello,2 Giovanni Luca Ceresoli1 1Department of Oncology, Thoracic and GU Oncology Unit, 2Department of Radiology, Cliniche Humanitas Gavazzeni, Bergamo, 3Nuclear Medicine Unit, Humanitas Clinical and Research Hospital, Milan, 4Department of Thoracic Surgery, Cliniche Humanitas Gavazzeni, Bergamo, Italy Abstract: Malignant pleural mesothelioma (MPM) is a disease with limited therapeutic options, the management of which is still controversial. Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological subtyping and is indicated for staging purposes in surgical candidates. The recommended and recently updated classification for clinical use is the TNM staging system established by the International Mesothelioma Interest Group and the International Association for the Study of Lung Cancer, which is based mainly on surgical and pathological variables, as well as on cross-sectional imaging. Contrast-enhanced computed tomography is the primary imaging procedure. Currently, the most used measurement system for MPM is the modified Response Evaluation Criteria in Solid Tumors (RECIST) method, which is based on unidimensional measurements of tumor thickness perpendicular to the chest wall or mediastinum. Magnetic resonance imaging and functional imaging with 18F-fluoro-2-deoxy-d-glucose positron-emission tomography can provide additional staging information in selected cases, although the usefulness of this method is limited in patients undergoing pleurodesis. Molecular reclassification of MPM and gene expression or miRNA prognostic models have the potential to improve prognostication and patient selection for a proper treatment algorithm; however, they await prospective validation to be introduced in clinical practice. Keywords: malignant pleural mesothelioma, staging, contrast-enhanced computed tomography, magnetic resonance imaging, positron-emission tomographyBonomi MDe Filippis CLopci EGianoncelli LRizzardi GCerchiaro EBortolotti LZanello ACeresoli GLDove Medical PressarticleMalignant Pleural MesotheliomaStagingContrast-enhanced computed tomographyMagnetic res-onance imagingPositron emission tomographyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 127-139 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Malignant Pleural Mesothelioma Staging Contrast-enhanced computed tomography Magnetic res-onance imaging Positron emission tomography Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Malignant Pleural Mesothelioma Staging Contrast-enhanced computed tomography Magnetic res-onance imaging Positron emission tomography Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Bonomi M De Filippis C Lopci E Gianoncelli L Rizzardi G Cerchiaro E Bortolotti L Zanello A Ceresoli GL Clinical staging of malignant pleural mesothelioma: current perspectives
description	Maria Bonomi,1 Costantino De Filippis,2 Egesta Lopci,3 Letizia Gianoncelli,1 Giovanna Rizzardi,4 Eleonora Cerchiaro,1 Luigi Bortolotti,4 Alessandro Zanello,2 Giovanni Luca Ceresoli1 1Department of Oncology, Thoracic and GU Oncology Unit, 2Department of Radiology, Cliniche Humanitas Gavazzeni, Bergamo, 3Nuclear Medicine Unit, Humanitas Clinical and Research Hospital, Milan, 4Department of Thoracic Surgery, Cliniche Humanitas Gavazzeni, Bergamo, Italy Abstract: Malignant pleural mesothelioma (MPM) is a disease with limited therapeutic options, the management of which is still controversial. Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological subtyping and is indicated for staging purposes in surgical candidates. The recommended and recently updated classification for clinical use is the TNM staging system established by the International Mesothelioma Interest Group and the International Association for the Study of Lung Cancer, which is based mainly on surgical and pathological variables, as well as on cross-sectional imaging. Contrast-enhanced computed tomography is the primary imaging procedure. Currently, the most used measurement system for MPM is the modified Response Evaluation Criteria in Solid Tumors (RECIST) method, which is based on unidimensional measurements of tumor thickness perpendicular to the chest wall or mediastinum. Magnetic resonance imaging and functional imaging with 18F-fluoro-2-deoxy-d-glucose positron-emission tomography can provide additional staging information in selected cases, although the usefulness of this method is limited in patients undergoing pleurodesis. Molecular reclassification of MPM and gene expression or miRNA prognostic models have the potential to improve prognostication and patient selection for a proper treatment algorithm; however, they await prospective validation to be introduced in clinical practice. Keywords: malignant pleural mesothelioma, staging, contrast-enhanced computed tomography, magnetic resonance imaging, positron-emission tomography
format	article
author	Bonomi M De Filippis C Lopci E Gianoncelli L Rizzardi G Cerchiaro E Bortolotti L Zanello A Ceresoli GL
author_facet	Bonomi M De Filippis C Lopci E Gianoncelli L Rizzardi G Cerchiaro E Bortolotti L Zanello A Ceresoli GL
author_sort	Bonomi M
title	Clinical staging of malignant pleural mesothelioma: current perspectives
title_short	Clinical staging of malignant pleural mesothelioma: current perspectives
title_full	Clinical staging of malignant pleural mesothelioma: current perspectives
title_fullStr	Clinical staging of malignant pleural mesothelioma: current perspectives
title_full_unstemmed	Clinical staging of malignant pleural mesothelioma: current perspectives
title_sort	clinical staging of malignant pleural mesothelioma: current perspectives
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/ebedbd0f69fe4aa0b1a62eaa190b0c5b
work_keys_str_mv	AT bonomim clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT defilippisc clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT lopcie clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT gianoncellil clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT rizzardig clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT cerchiaroe clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT bortolottil clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT zanelloa clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives AT ceresoligl clinicalstagingofmalignantpleuralmesotheliomacurrentperspectives
_version_	1718399609995264000

Clinical staging of malignant pleural mesothelioma: current perspectives

Ejemplares similares